IFCC Feed2020-08-04T19:21:57Z Insoft Feed Generator /ifcc-news/ 2020-07-30T14:23:59Z /ifcc-news/2020-07-30-prof-donald-young/ IFCC Office

 

Dr S. Donald Young became IFCC President in 1985, after a three-year term as Vice-President. During his six years as President, Dr Young reorganised the committee structure of the IFCC. The previous Expert Panels were redefined as Committees and an integrated structure was formed to allow better communications and delegation of responsibility and activity. Dr Young initiated a further review and modification of the IFCC Statutes which was completed in 1993. During Dr Young’s tenure IFCC initiated the publication of its own journal - Journal of the International Federation of Clinical Chemistry. A broader interpretation of clinical chemistry to include other areas of laboratory medicine was developed. Formal associations were initiated with clinical chemistry organisations in Latin America and the Asian and Pacific region.

He was always helping colleagues in Africa and he assisted in bringing IFCC and ASLM together in putting up a MOU. He took a keen role in the Mentorship program especially in Africa.

Not only did he play a key role in the IFCC but he was one of the pillars of Clinical Chemistry having published one of the few books on the effect of drugs and other interferences  on Clinical Chemistry tests. 

Dr. Young was born in Belfast, Northern Ireland, and completed his Bachelor of Medicine at the University of Aberdeen in Scotland in 1957. In 1962 he was granted a PhD in Chemical Pathology from the University of London.

Donald Young received a Leverhulme Fellowship of Royal Society of Medicine, Royal Postgraduate Medical School, London, and then trained as a Registrar (Resident) in Chemical Pathology at the Royal Postgraduate Medical School and as Honorary Registrar, Hammersmith Hospital, in London. He moved to the US and in 1965, he was appointed a Visiting Scientist in the Clinical Pathology Department at the National Institutes of Health in Bethesda, Maryland, where he became the Chief of the Clinical Chemistry Service.

He is well known for his work as the principal editor and driving force behind the monumental Effects Series, a landmark collection of texts on the effects of drugs, disease, preanalytical variables, and herbals on laboratory tests. He spearheaded the transition of this work to an online database with information on more than 135,000 effects on more than 5,000 tests.

Dr. Young was the acting director of clinical chemistry at the Hospital of the University of Pennsylvania. He has been active in the AACC for many years, and served it in many capacities, including as president, council chair, and publications board chair. He has served on the executive council of the Academy of Clinical Laboratory Physicians and Scientists and as co-chair of four of its annual meetings. He chaired the automation commission of the International Union of Pure and Applied Chemistry. 

He has served on many government advisory committees, including for the National Institute of Standards and Technology, Food and Drug Administration, Centers for Disease Control and Prevention, and National Institutes of Health. He has served on the editorial boards of a variety of journals, including Clinical Chemistry (which he chaired), Analytical Letters, and Journal of Pharmaceutical and Biochemical Analysis. He has published more than 200 papers and book chapters, and edited influential books, including the Directory of Rare Analyses, Effects of Drugs on Clinical Laboratory Tests, and Effects of Disease on Clinical Laboratory Tests.

Dr. Young’s research interests have been directly associated with improvements in laboratory performance, optimizing the usefulness of laboratory data, use of computers, and evaluating usefulness of new analytical concepts such as microcalorimetry, the miniature centrifugal analyzer, and kinetic nephelometry. He has worked with the National Bureau of Standards on developing Reference Methods. During his long and successful career he received many Awards. in 2008 he received the IFCC-Howard Morris Distinguished Clinical Chemist Award (since 2020) IFCC Distinguished Clinical Chemist Award (1969-2017).

His colleagues at Penn describe Prof Young as a "tireless, dedicated" professional, who, while "committed to the highest standards," was a person of "stamina and patience" at the same time, "with an impressive reputation world-wide." He is remembered as "amiable, encouraging, and very supportive of the faculty and staff," as a "wise mentor," as well as a "generous and honorable gentleman."

Prof Young will be remembered as a mentor and role model for many Clinical Biochemistry colleagues and he will be greatly missed.

]]> IFCC Information Guide on COVID-19 - Monday 27 July updates2020-07-27T09:22:11Z /ifcc-news/2020-03-26-ifcc-information-guide-on-covid-19/ IFCC Office

 

 

 

IFCC Information Guide on COVID-19

Click aquí para descargar el Resumen traducido de la Guía de Información de la IFCC sobre COVID-19
Kliknutím zde stáhnete českou verzi IFCC informačního  souhrnu o COVID 19 z 16 . dubna 2020

 

 

 

 

Coronavirus disease 2019, abbreviated to COVID-19, is an emerging global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As the number of individuals infected with COVID-19 continues to rise globally and healthcare systems become increasingly stressed, it is clear that the clinical laboratory will play an essential role in this crisis, contributing to patient screening, diagnosis, monitoring/treatment, as well as epidemiologic recovery/surveillance. This guide aims to organize relevant available information on laboratory screening, testing protocols, diagnosis, and other general information on COVID-19 for laboratory professionals, including links to helpful resources and interim guidelines. It will be continually updated as new guidelines and literature become available.

 

 

 

 

 

Table of Contents:

  1. General Information
  2. Patient Screening
  3. Diagnostic Testing
  4. Biosafety Guidelines for the Clinical Laboratory
  5. Biochemical Monitoring of COVID-19 Patients
  6. Other Educational Materials & Webinars
  7. Big Data Tools

_____________________________________________________________________

 

 

1. General Information:

Please find below links to helpful websites and guidelines that have been put together by laboratory and clinical specialists from all over the world:

Key IFCC Publications:

Biosafety measures for preventing infection from COVID-19 in clinical laboratories:
IFCC Taskforce Recommendations.

Molecular, serological, and biochemical diagnosis and monitoring of COVID-19:
IFCC taskforce evaluation of the latest evidence

Laboratory Practices to Mitigate Biohazard Risks During the COVID-19 Outbreak: An IFCC Global Survey

Operational Considerations and Challenges of Biochemistry Laboratories During the COVID-19 Outbreak: An IFCC Global Survey

 

Key Resources:

American Association for Clinical Chemistry: COVID-19 Resources for Labs

Center for Disease Control: Information for Laboratories

European Centre for Disease Prevention and Control: COVID-19 Resources

National Institute for Health: COVID-19 Information Page

Royal College of Pathologists Australasia: Useful COVID-19 Resources

Royal College of Pathologists UK: COVID-19 Recommendations

World Health Organization: COVID-19 Technical Guidance for National Laboratories

Scientific Journal Resources:

British Medical Journal: COVID-19 Best Practice Guideline

Journal of the American Medical Association (JAMA): Coronavirus Disease 2019 (COVID-19)

New England Journal of Medicine (NEJM): Coronavirus (Covid-19)

Springer Nature: Latest Research in COVID-19

 

Global Practice Guidelines/Handbooks:

Rapid health technology assessment of alternative diagnostic testing approaches for the detection of severe acute respiratory syndrome coronavirus 2 (Health Information and Quality Authority, Ireland)

Guidelines for Laboratory Diagnosis of Coronavirus Disease 2019 (COVID-19) (Korea)

Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (Provisional 7th Edition, Chinese Guidelines)

Handbook of COVID-19 Prevention and Treatment (Zhejiang University School of Medicine)

Handbook for COVID-19 Laboratory  Management (Sociedade Brasileira de Analises Clinicas  - Portuguese and English)

Orientative Guide on Quality Management for Laboratory Diagnosis of COVID-19 (OBBCSSR, Romania)

 

Other Resources:

Association for Quality Management in Laboratory Medicine: COVID-19 resources

The Canadian Public Health Laboratory Network: Resources

FIND Diagnostics: COVID-19 Diagnostics Research Centre

Joint Commission International: COVID-19 Guidance & Resources

Oxford Centre for Evidence-Based Medicine: COVID-19 Evidence Service

Medscape: A Quick Summary of the COVID-19 Literature So Far

Public Health Ontario: Coronavirus Disease 2019 (COVID-19) Testing

Singapore Resources: Practice Recommendations, Preparing Labs, Current Experience

The Scientist Magazine: Follow the Coronavirus Outbreak

 

_____________________________________________________________________

 

 

2. Patient Screening

According to the World Health Organization (WHO) guide for Global surveillance for COVID-19 caused by human infection with COVID-19 virus, a suspect case is defined as:

  1. A patient with acute respiratory illness (fever and at least one sign/symptom of respiratory disease, e.g., cough, shortness of breath), AND a history of travel to or residence in a location reporting community transmission of COVID-19 disease during the 14 days prior to symptom onset; OR
  2. A patient with any acute respiratory illness AND having been in contact with a confirmed or probable COVID-19 case (see definition of contact) in the last 14 days prior to symptom onset; OR
  1. A patient with severe acute respiratory illness (fever and at least one sign/symptom of respiratory disease, e.g., cough, shortness of breath; AND requiring hospitalization) AND in the absence of an alternative diagnosis that fully explains the clinical presentation.

A probable case is defined as:

  1. A suspect case for whom testing for the COVID-19 virus is inconclusive; OR
  2. A suspect case for whom testing could not be performed for any reason.

A confirmed case is defined as:

A person with laboratory confirmation of COVID-19 infection, irrespective of clinical signs and symptoms.  See laboratory guidance for details.

 _____________________________________________________________________

 

 

 

3. Diagnostic Testing: Analytical and Clinical Aspects

Upon confirmation of a suspected case, specimens should be rapidly collected and tested. The Centers for Disease Control and Prevention (CDC) Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons for Coronavirus Disease 2019 (updated April 8th) recommends collecting an upper respiratory specimen for initial diagnostic testing. The following specimens can be collected for swab-based testing: Nasopharyngeal specimen (preferred), Oropharyngeal specimen, Nasal mid-turbinate specimen and Anterior nares specimen. Lower respiratory tract specimen testing is also recommended by the CDC, if the specimens are available.

 

 

 

Nucleic Acid Amplification Tests (NAAT)

Real-time reverse transcription polymerase chain reaction (rRT-PCR) is the current gold standard for diagnosing suspected cases of COVID-19. rRT-PCR is a nucleic acid amplification test (NAAT) that detects unique sequences of the virus that causes COVID-19 (SARS-CoV-2) in respiratory tract specimens. The N, E, S, and RdRP are the viral genes currently targeted (WHO,  Laboratory testing for coronavirus disease (COVID-19) in suspected human cases). A validated diagnostic workflow for detecting SARS-CoV-2 has been recently published by Corman and colleagues (PMID: 31992387), as follows: (a) First line screening: E gene, (b) Confirmatory screening: RdRP gene, and (c) Additional confirmatory screening: N gene.

The following table presents criteria for a case to be considered as laboratory-confirmed by validated NAAT assays according to the WHO:

In some cases, a negative result may be returned for a suspected case with a high likelihood of COVID-19 infection. If the negative result was concluded based on only an upper respiratory tract specimen, a lower respiratory tract specimen should be subsequently tested. Additional specimens eligible for testing include blood and stool (WHO, Laboratory testing for coronavirus disease (COVID-19) in suspected human cases).

Antigen Testing

Antigen assays belong to an additional class of pathogen detecting assays. They detect SATS-CoV-2 antigen in virtually the same sample types as molecular test. These types of assays have already used in the past for other respiratory diseases like influenza and are usually POC tests. There are known to have a good specificity, but a limited sensitivity compared to NAAT. Advantages are an almost instant result and lower cost compared to NAAT. They allow an early rule-in of patients. Negative results, however, still require follow-up NAAT testing. One antigen assay recently got an FDA EUA authorization the Quidel Sofia® 2 SARS Antigen FIA. 

 

Currently Available Diagnostic Assays

Several in-house and commercial assays are currently being developed and optimized. Links to currently available in-house protocols can be accessed here via the World Health Organization. Countries who have no testing capacity or national COVID-19 laboratories with limited experience on COVID-19 testing are encouraged to send the first five positives and the first ten negative COVID-19 samples to WHO reference laboratories providing confirmatory testing for COVID-19. Additionally, the WHO also released a Laboratory Assessment Tool (LAT) which is designed to assess the capacity of existing laboratories which aim to implement COVID-19 testing: Access the tool!

List of FDA Approved Molecular Diagnostic Assays

FDA Policy for Emergency Approval

List of Health Canada Approved Molecular Diagnostic Assays

European Commission Guidelines on COVID-19 in vitro diagnostic tests and their performance

FIND Diagnostics: Diagnostic Performance Data of Molecular and Serology Testing

Pre-analytical and Analytical Testing Issues

There are various pre-analytical and analytical issues that can affect diagnostic testing for COVID-19 infection. Some pre-analytical issues include improper collection, handling, transport and usage of swabs, as well as collection of inappropriate or inadequate material, interfering substances, and sample contamination. A common analytical issue is testing outside of the diagnostic window, in addition to active viral recombination and inadequately validated assays (PMID: 31992387).

In order to increase testing capacity and provide more flexible options for SARS-CoV-2 RNA screening, the prospect of patient self-collection of samples has been recently discussed. Indeed, the FDA recently authorized the first home test kit for COVID-19 (April 20 2020). While expanding consumer access to COVID-19 is important, various preanalytical considerations need to be considered, affecting sample quality and impacting result accuracy.  These concerns are summarized in a recent letter from the AACC and supported by a recent publication by Sullivan and colleagues (PMID: 32310815).

Serological Testing:

There has been much debate regarding the current value of serological testing in COVID-19 diagnosis and monitoring. Serologic based tests are not currently recommended by the CDC, NHS or other health organizations.  There is general concern regarding their use in the acute phase of infection as they detect infection too late in the course of illness (usually more than 7-10 days), they also may cross-react with serologic responses to seasonal coronaviruses and the rate and kinetics of serological response has not been clearly defined so far. However, there is anticipated value in using improved serological testing in the future for public and occupational health monitoring and assessment. Key publications are listed below.

 

 

Key Publications on Diagnostic and Serology Testing: 

Molecular Testing:

  1. Wang X, Yao H, Xu X, Zhang P, Zhang M, Shao J, Xiao Y, Wang H. Limits of Detection of Six Approved RT–PCR Kits for the Novel SARS-coronavirus-2 (SARS-CoV-2). Clinical Chemistry. 2020 Apr 13. PMID: 32282874
  2. Lippi G, Simundic AM, Plebani M. Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19). Clinical Chemistry and Laboratory Medicine (CCLM). 2020 Mar 16;1(ahead-of-print). PMID: 32172228
  3. Sung H, Yoo CK, Han MG, Lee SW, Lee H, Chun S, Lee WG, Min WK. Preparedness and Rapid Implementation of External Quality Assessment Helped Quickly Increase COVID-19 Testing Capacity in the Republic of Korea. Clinical Chemistry. PMID: 32321159
  4. Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, Tao Q, Sun Z, Xia L. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology. 2020 Feb 26:200642. PMID: 32101510
  5. Lassaunière R, Frische A, Harboe ZB, Nielsen AC, Fomsgaard A, Krogfelt KA, Jørgensen CS. Evaluation of nine commercial SARS-CoV-2 immunoassays. 2020 Jan 1
  6. Hanley B, Lucas SB, Youd E, Swift B, Osborn M. Autopsy in suspected COVID-19 cases. Journal of Clinical Pathology. 2020 May 1;73(5):239-42. PMID: 32198191
  7. Zhen W, Manji R, Smith E, Berry GJ. Comparison of Four Molecular In Vitro Diagnostic Assays for the Detection of SARS-CoV-2 in Nasopharyngeal Specimens. Journal of Clinical Microbiology. 2020 Apr 27. PMID: 32341143
  8. Lin C, Xiang J, Yan M, Li H, Huang S, Shen C. Comparison of throat swabs and sputum specimens for viral nucleic acid detection in 52 cases of novel coronavirus (SARS-Cov-2)-infected pneumonia (COVID-19). Clinical Chemistry and Laboratory Medicine (CCLM). 2020 Apr 16;1(ahead-of-print). PMID: 32301745
  9. Pan Y, Long L, Zhang D, Yan T, Cui S, Yang P, Wang Q, Ren S. Potential false-negative nucleic acid testing results for Severe Acute Respiratory Syndrome Coronavirus 2 from thermal inactivation of samples with low viral loads. Clinical Chemistry. 2020 Apr 4. PMID: 32246822
  10. Behrmann O, Bachmann I, Spiegel M, et al. Rapid detection of SARS-CoV-2 by low volume real-time single tube reverse transcription recombinase polymerase amplification using an exo probe with an internally linked quencher (exo-IQ). Clinical Chemistry. 2020 May 8. PMID: 32384153
  11. Peddu V, Shean RC, Xie H, et al. Metagenomic analysis reveals clinical SARS-CoV-2 infection and bacterial or viral superinfection and colonization. Clinical Chemistry. 2020 May 7. PMID: 32379863
  12. Dietzen DJ. Unleashing the Power of Laboratory Developed Tests: Closing gaps in COVID diagnosis and beyond. The Journal of Applied Laboratory Medicine. 2020 Apr 29.
  13. Basu A, Zinger T, Inglima K, Woo KM, Atie O, Yurasits L, See B, Aguero-Rosenfeld ME. Performance of the rapid Nucleic Acid Amplification by Abbott ID NOW COVID-19 in nasopharyngeal swabs transported in viral media and dry nasal swabs, in a New York City academic institution. bioRxiv. 2020 Jan 1. Preprint non-peer reviewed
  14. Ramdas K, Darzi A, Jain S. ‘Test, re-test, re-test’: using inaccurate tests to greatly increase the accuracy of COVID-19 testing. Nature Medicine. 2020 May 12:1-2. PMID: 32398878
  15. Wacharapluesadee S, Kaewpom T, Ampoot W, et al. Evaluating the efficiency of specimen pooling for PCR-based detection of COVID-19. J Med Virol. 2020 May 13;10.1002/jmv.26005. PMID: 32401343
  16. Basu A, Zinger T, Inglima K, Woo KM, Atie O, Yurasits L, See B, Aguero-Rosenfeld ME. Performance of Abbott ID NOW COVID-19 rapid nucleic acid amplification test in nasopharyngeal swabs transported in viral media and dry nasal swabs, in a New York City academic institution. J Clin Microbiol. 2020 May 29:JCM.01136-20. doi: 10.1128/JCM.01136-20. Epub ahead of print. PMID: 32471894.
  17. Traugott M, Aberle SW, Aberle JH, Griebler H, Karolyi M, Pawelka E, Puchhammer-Stöckl E, Zoufaly A, Weseslindtner L. Performance of SARS-CoV-2 antibody assays in different stages of the infection: Comparison of commercial ELISA and rapid tests. J Infect Dis. 2020 May 30:jiaa305. doi: 10.1093/infdis/jiaa305. Epub ahead of print. PMID: 32473021.
  18. Binnicker MJ. Emergence of a Novel Coronavirus Disease (COVID-19) and the Importance of Diagnostic Testing: Why Partnership between Clinical Laboratories, Public Health Agencies, and Industry Is Essential to Control the Outbreak. Clin Chem. 2020;66(5):664‐ doi:10.1093/clinchem/hvaa071. PMID: 32077933
  19. Shi J, Han D, Zhang R, Li J, Zhang R. Molecular and serological assays for SARS-CoV-2: insights from genome and clinical characteristics. Clin Chem. 2020 May 21:hvaa122. doi: 10.1093/clinchem/hvaa122. Epub ahead of print. PMID: 32437513.
  20. Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2 Tests by Time Since Exposure. Annals of Internal Medicine. 2020 May 23. PMID: 32422057
  21. Jehi L, Ji X, Milinovich A, Erzurum S, Rubin B, Gordon S, Young J, Kattan MW. Individualizing risk prediction for positive COVID-19 testing: results from 11,672 patients. Chest. 2020 Jun 10. doi: 10.1016/j.chest.2020.05.580. Epub ahead of print. PMCID: PMC7286244.
  22. Pilcher CD, Westreich D, Hudgens MG. Group Testing for Sars-Cov-2 to Enable Rapid Scale-Up of Testing and Real-Time Surveillance of Incidence [published online ahead of print, 2020 Jun 27]. J Infect Dis. 2020;jiaa378. doi:10.1093/infdis/jiaa378
  23. Vogels CBF, Brito AF, Wyllie AL, et al. Analytical sensitivity and efficiency comparisons of SARS-CoV-2 RT-qPCR primer-probe sets [published online ahead of print, 2020 Jul 10]. Nat Microbiol. 2020;10.1038/s41564-020-0761-6. doi:10.1038/s41564-020-0761-6
  24. Fung B, Gopez A, Servellita V, et al. Direct Comparison of SARS-CoV-2 Analytical Limits of Detection across Seven Molecular Assays [published online ahead of print, 2020 Jul 10]. J Clin Microbiol. 2020;JCM.01535-20. doi:10.1128/JCM.01535-20
  25. Mallett S, Allen J, Graziadio S, Taylor SA, Sakai NS, Green K, Suklan J, Hyde C, Shinkins B, Zhelev Z, Peters J. At what times during infection is SARS-CoV-2 detectable and no longer detectable using RT-PCR based tests?: A systematic review of individual participant data. 2020 Jan 1.
  26. Mattiuzzi C, Henry BM, Sanchis-Gomar F, Lippi G. SARS-CoV-2 recurrent RNA positivity after recovering from coronavirus disease 2019 (COVID-19): a meta-analysis. Acta BioMed. 2020;91(3): Epub ahead of print. Doi: 10.23750/abm.v91i3.10303
  27. Artesi M, Bontems S, Göbbels P, Franckh M, Maes P, Boreux R, Meex C, Melin P, Hayette MP, Bours V, Durkin K. A recurrent mutation at position 26,340 of SARS-CoV-2 is associated with failure of the E-gene qRT-PCR utilized in a commercial dual-target diagnostic assay. Journal of Clinical Microbiology. 2020 Jul 20.
  28. Matheeussen V, Corman VM, Mantke OD, McCulloch E, Lammens C, Goossens H, Niemeyer D, Wallace PS, Klapper P, Niesters HG, Drosten C. International external quality assessment for SARS-CoV-2 molecular detection and survey on clinical laboratory preparedness during the COVID-19 pandemic, April/May 2020. Eurosurveillance. 2020 Jul 9;25(27):2001223.
  29. Bossuyt PM. Testing COVID-19 tests faces methodological challenges. Journal of Clinical Epidemiology. 2020 Jul 3.

Antigen Testing:

  1. Selove W, Rao LV. Performance of rapid SOFIA Influenza A+ B test compared to Luminex x-TAG respiratory viral panel assay in the diagnosis of influenza A, B, and subtype H3. Journal of Investigative Medicine. 2016 Apr 1;64(4):905-7. PMID: 26911275
  2. Blairon L, Wilmet A, Beukinga I, Tré-Hardy M. Implementation of rapid SARS-CoV-2 antigenic testing in a laboratory without access to molecular methods: experiences of a general hospital. Journal of Clinical Virology. 2020 May 30:104472. PMID: 32504944
  3. Mak GC, Cheng PK, Lau SS, et al. Evaluation of rapid antigen test for detection of SARS-CoV-2 virus [published online ahead of print, 2020 Jun 8]. J Clin Virol. 2020;129:104500. doi:10.1016/j.jcv.2020.104500

Serology Testing:

  1. Ju B, Zhang Q, Ge X, Wang R, Yu J, Shan S, Zhou B, Song S, Tang X, Yu J, Ge J. Potent human neutralizing antibodies elicited by SARS-CoV-2 infection. bioRxiv. 2020 Jan 1.
  2. Castro R, Luz PM, Wakimoto MD, Veloso VG, Grinsztejn B, Perazzo H. COVID-19: a meta-analysis of diagnostic test accuracy of commercial assays registered in Brazil. The Brazilian Journal of Infectious Diseases. 2020 Apr 18. PMID: 32330437
  3. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, Wang X, Yuan J, Li T, Li J, Qian S. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clinical Infectious Diseases. 2020 Jan 1. PMID: 32221519
  4. Iwasaki A, Yang Y. The potential danger of suboptimal antibody responses in COVID-19. Nature Reviews Immunology. 2020 Apr 21:1-3. PMID: 32317716
  5. Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, Ling Y, Zhang Y, Xun J, Lu L, Jiang S. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. Preprint at medrxiv
  6. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M, Chen L, Meng S, Hu Y, Peng C. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proceedings of the National Academy of Sciences. 2020 Apr 6. PMID: 32253318
  7. Kran AM. Evaluation of eleven rapid tests for detection of antibodies against SARS-CoV-2. 2020 Apr 24
  8. Padoan A, Cosma C, Sciacovelli L, Faggian D, Plebani M. Analytical performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kinetics. Clinical Chemistry and Laboratory Medicine (CCLM). 2020 Apr 16;1(ahead-of-print). PMID: 32301749
  9. Azzi L, Carcano G, Gianfagna F, Grossi P, Dalla Gasperina D, Genoni A, Fasano M, Sessa F, Tettamanti L, Carinci F, Maurino V. SALIVA IS A RELIABLE TOOL TO DETECT SARS-CoV-2. Journal of Infection. 2020 Apr 14. PMID: 32298676
  10. Perera RA, Mok CK, Tsang OT, Lv H, Ko RL, Wu NC, Yuan M, Leung WS, Chan JM, Chik TS, Choi CY. Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. Eurosurveillance. 2020 Apr 23;25(16):2000421. PMID: 32347204
  11. Zeng QL, Yu ZJ, Gou JJ, Li GM, Ma SH, Zhang GF, Xu JH, Lin WB, Cui GL, Zhang MM, Li C. Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19 Patients. The Journal of Infectious Diseases. 2020 Apr 29. PMID: 32348485
  12. Farnsworth CW, Anderson NW. SARS-CoV-2 Serology: Much Hype, Little Data. Clinical Chemistry. 2020 Apr 28. PMID: 32343775
  13. Bryan A, Pepper G, Wener MH, et al. Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho. J Clin Microbiol. 2020 May 7. PMID: 32381641
  14. Adams ER, Anand R, Andersson MI, Auckland K, Baillie JK, Barnes E, Bell J, Berry T, Bibi S, Carroll M, Chinnakannan S. Evaluation of antibody testing for SARS-Cov-2 using ELISA and lateral flow immunoassays. 2020 Jan 1 - non-peer reviewed
  15. Qu J, Wu C, Li X, Zhang G, Jiang Z, Li X, Liu L. Profile of IgG and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases. 2020 Apr 27. PMID: 32337590
  16. Anderson DE, Tan CW, Chia WN, Young BE, Linster M, Low JH, Tan YJ, Chen MI, Smith GJD, Leo YS, Lye DC, Wang LF. Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2. Emerg Microbes Infect. 2020 Dec;9(1):900-902. PMID: 32380903.
  17. Diamandis P, Prassas I, Diamandis EP. Antibody tests for COVID-19: drawing attention to the importance of analytical specificity. Clinical chemistry and laboratory medicine. 2020 May 9. PMID: 32386187
  18. Tang MS, Hock KG, Logsdon NM, et al. Clinical Performance of Two SARS-CoV-2 Serologic Assays. Clin Chem. May 13 2020;hvaa120. PMID: 32402061
  19. Montesinos I, Gruson D, Kabamba B, Dahma H, Van den Wijngaert S, Reza S, Carbone V, Vandenberg O, Gulbis B, Wolff F, Rodriguez-Villalobos H. Evaluation of two automated and three rapid lateral flow immunoassays for the detection of anti-SARS-CoV-2 antibodies. J Clin Virol. 2020 May 5;128:104413. PMID: 32403010
  20. Riccò M, Ferraro P, Gualerzi G, Ranzieri S, Henry BM, Said YB, Pyatigorskaya NV, Nevolina E, Wu J, Bragazzi NL, Signorelli C. Point-of-Care Diagnostic Tests for Detecting SARS-CoV-2 Antibodies: A Systematic Review and Meta-Analysis of Real-World Data. Journal of Clinical Medicine. 2020 May;9(5):1515. PMID: 32443459
  21. Kontou PI, Braliou GG, Dimou NL, Nikolopoulos G, Bagos PG. Antibody Tests in Detecting SARS-CoV-2 Infection: A Meta-Analysis. Diagnostics (Basel). 2020 May 19;10(5):E319. PMID: 32438677
  22. Kofler N, Baylis F. Ten reasons why immunity passports are a bad idea. Nature. 2020 May;581(7809):379-381 (opinion). PMID: 32439992
  23. Dinges et al. Seroprevalence of SARS-CoV-2 among children visiting a hospital during the initial Seattle outbreak (non-peer reviewed). https://doi.org/10.1101/2020.05.26.20114124
  24. Nuccetelli M, Pieri M, Grelli S, Ciotti M, Miano R, Andreoni M, Bernardini S. SARS-CoV-2 infection serology: a useful tool to overcome lockdown?. Cell Death Discovery. 2020 May 26;6(1):1-9.
  25. Ong DS, Stijn J, Lindeboom FA, Koeleman JG. Comparison of diagnostic accuracies of rapid serological tests and ELISA to molecular diagnostics in patients with suspected COVID-19 presenting to the hospital. Clinical Microbiology and Infection. 2020 Jun 2. PMID: 32502646
  26. Tang MS, Hock KG, Logsdon NM, Hayes JE, Gronowski AM, Anderson NW, Farnsworth CW. Clinical Performance of the Roche SARS-CoV-2 Serologic Assay. Clin Chem. 2020 Jun 2:hvaa132. doi: 10.1093/clinchem/hvaa132. Epub ahead of print. PMID: 32484860.
  27. Bermingham WH, Wilding T, Beck S, Huissoon A. SARS-CoV-2 serology: Test, test, test, but interpret with caution! Clin Med (Lond). 2020 Jun 2:clinmed.2020-0170. doi: 10.7861/clinmed.2020-0170. Epub ahead of print. PMID: 32487681.
  28. Beavis KG, Matushek SM, Abeleda APF, Bethel C, Hunt C, Gillen S, Moran A, Tesic V. Evaluation of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies. J Clin Virol. 2020 May 23;129:104468. doi: 10.1016/j.jcv.2020.104468. Epub ahead of print. PMID: 32485620; PMCID: PMC7255182.
  29. Plebani M, Padoan A, Negrini D, Carpinteri B, Sciacovelli L. Diagnostic performances and thresholds: the key to harmonization in serological SARS-CoV-2 assays? [published online ahead of print, 2020 May 30]. Clin Chim Acta. 2020;S0009-8981(20)30263-1. doi:10.1016/j.cca.2020.05.050. PMID: 32485157
  30. Egger M, Bundschuh C, Wiesinger K, Gabriel C, Clodi M, Mueller T, Dieplinger B. Comparison of the Elecsys® Anti-SARS-CoV-2 immunoassay with the EDITMenzyme linked immunosorbent assays for the detection of SARS-CoV-2 antibodies in human plasma. Clin Chim Acta. 2020 May 30:S0009-8981(20)30261-8. doi: 10.1016/j.cca.2020.05.049. Epub ahead of print. PMID: 32485155; PMCID: PMC7261064.
  31. Bélec L, Péré H, Bouassa RM, Veyer D, Jenabian MA. Potential pitfalls of routine SARS-CoV-2 serology for mass screening. J Med Virol. 2020 Jun 2. doi: 10.1002/jmv.26034. Epub ahead of print. PMID: 32484942.
  32. Eroshenko N, Gill T, Keaveney MK, Church GM, Trevejo JM, Rajaniemi H. Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures. Nat Biotechnol. 2020 Jun 5. doi: 10.1038/s41587-020-0577-1. Epub ahead of print. PMID: 32504046.
  33. To KK, Cheng VC, Cai JP, Chan KH, Chen LL, Wong LH, Choi CY, Fong CH, Ng AC, Lu L, Luo CT. Seroprevalence of SARS-CoV-2 in Hong Kong and in residents evacuated from Hubei province, China: a multicohort study. The Lancet Microbe. 2020 Jun 3. DOI:https://doi.org/10.1016/S2666-5247(20)30053-7
  34. Luchsinger LL, Ransegnola B, Jin D, Muecksch F, Weisblum Y, Bao W, George PJ, Rodriguez M, Tricoche N, Schmidt F, Gao C. Serological Analysis of New York City COVID19 Convalescent Plasma Donors. medRxiv. 2020 Jan 1. https://doi.org/10.1101/2020.06.08.20124792
  35. Behrens GMN, Cossmann A, Stankov MV, Witte T, Ernst D, Happle C, Jablonka A. Perceived versus proven SARS-CoV-2-specific immune responses in health-care professionals. Infection. 2020 Jun 10:1–4. doi: 10.1007/s15010-020-01461-0. Epub ahead of print. PMID: 32524515; PMCID: PMC7286418.
  36. Chew KL, Tan SS, Saw S, Pajarillaga A, Zaine S, Khoo C, Wang W, Tambyah P, Jureen R, Sethi SK. Clinical evaluation of serological IgG antibody response on the Abbott Architect for established SARS-CoV-2 infection. Clinical Microbiology and Infection. 2020 Jun 9. PMID: 32531475
  37. Premkumar L, Segovia-Chumbez B, Jadi R, et al. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol. 2020;5(48):eabc8413. doi:10.1126/sciimmunol.abc8413
  38. Theel ES, Harring J, Hilgart H, Granger D. Performance Characteristics of Four High-Throughput Immunoassays for Detection of IgG Antibodies against SARS-CoV-2 [published online ahead of print, 2020 Jun 8]. J Clin Microbiol. 2020;JCM.01243-20. doi:10.1128/JCM.01243-20
  39. Sarina Yang H, Racine-Brzostek SE, Lee WT, et al. SARS-CoV-2 antibody characterization in emergency department, hospitalized and convalescent patients by two semi-quantitative immunoassays [published online ahead of print, 2020 Jun 4]. Clin Chim Acta. 2020;509:117‐ doi:10.1016/j.cca.2020.06.004
  40. Respiratory Virus Infections Working Group1. Canadian Public Health Laboratory Network Statement on Point-of-Care Serology Testing in COVID-19. Can Commun Dis Rep. 2020 May 7;46(5):119-120. doi: 10.14745/ccdr.v46i05a03. PMID: 32558808; PMCID:
  41. Caini S, Bellerba F, Corso F, Díaz-Basabe A, Natoli G, Paget J, Facciotti F, De Angelis SP, Raimondi S, Palli D, Mazzarella L, Pelicci PG, Vineis P, Gandini S. Meta-analysis of diagnostic performance of serological tests for SARS-CoV-2 antibodies up to 25 April 2020 and public health implications. Euro Surveill. 2020 Jun;25(23). doi: 10.2807/1560-7917.ES.2020.25.23.2000980. PMID:
  42. A Path Forward for SRAS-CoV-2 Testing. https://www.aacc.org/publications/cln/cln-stat/2020/june/18/a-path-forward-for-sars-cov-2-testing
  43. Jääskeläinen AJ, Kuivanen S, Kekäläinen E, Ahava MJ, Loginov R, Kallio-Kokko H, Vapalahti O, Jarva H, Kurkela S, Lappalainen M. Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation. J Clin Virol. 2020 Jun 15;129:104512. doi: 10.1016/j.jcv.2020.104512. Epub ahead of print. PMID: 32563180.
  44. Wang P. Combination of Serological Total Antibody and RT-PCR Test for Detection of SARS-CoV-2 Infections. J Virol Methods. 2020 Jun 15;283:113919. doi: 10.1016/j.jviromet.2020.113919. Epub ahead of print. PMID: 32554043
  45. Han X, Wei X, Alwalid O, Cao Y, Li Y, Wang L, Shi H. Severe Acute Respiratory Syndrome Coronavirus 2 among Asymptomatic Workers Screened for Work Resumption, China. Emerg Infect Dis. 2020 Jun 17;26(9). doi: 10.3201/eid2609.201848. Epub ahead of print. PMID: 32553070.
  46. Clapham H, Hay J, Routledge I, Takahashi S, Choisy M, Cummings D, Grenfell B, Metcalf CJE, Mina M, Barraquer IR, Salje H, Tam CC. Seroepidemiologic Study Designs for Determining SARS-COV-2 Transmission and Immunity. Emerg Infect Dis. 2020 Jun 16;26(9). doi: 10.3201/eid2609.201840. Epub ahead of print. PMID: 32544053.
  47. Liu ZL, Liu Y, Wan LG, Xiang TX, Le AP, Liu P, Peiris M, Poon LLM, Zhang W. Antibody profiles in mild and severe cases of COVID-19. Clin Chem. 2020 Jun 10:hvaa137. doi: 10.1093/clinchem/hvaa137. Epub ahead of print. PMID: 32521002.
  48. Favresse J, Eucher C, Elsen M, Marie TH, Dogné JM, Douxfils J. Clinical performance of the Elecsys electrochemiluminescent immunoassay for the detection of SARS-CoV-2 total antibodies. Clin Chem. 2020 Jun 2:hvaa131. doi: 10.1093/clinchem/hvaa131. Epub ahead of print. PMID: 32484887.
  49. Lerner AM, Eisinger RW, Lowy DR, Petersen LR, Humes R, Hepburn M, Cassetti MC. The COVID-19 Serology Studies Workshop: Recommendations and Challenges. Immunity. 2020 Jun 23. https://doi.org/10.1016/j.immuni.2020.06.012
  50. Nicol T, Lefeuvre C, Serri O, et al. Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of three immunoassays: Two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay (NG Biotech) [published online ahead of print, 2020 Jun 15]. J Clin Virol. 2020;129:104511. doi:10.1016/j.jcv.2020.104511
  51. Yan M, Zheng Y, Sun Y, et al. Analysis of the diagnostic value of serum specific antibody testing for coronavirus disease 2019 [published online ahead of print, 2020 Jun 27]. J Med Virol. 2020;10.1002/jmv.26230. doi:10.1002/jmv.26230
  52. Christenson RH. Out of the Darkness-Into the Light: Value of SARS-CoV-2 Antibody Testing in Populations to Benefit Public Health and in Individuals for Peace of Mind [published online ahead of print, 2020 Jun 27]. J Appl Lab Med. 2020;jfaa105. doi:10.1093/jalm/jfaa105
  53. Espejo AP, Akgun Y, Al Mana AF, et al. Review of Current Advances in Serologic Testing for COVID-19 [published online ahead of print, 2020 Jun 25]. Am J Clin Pathol. 2020;aqaa112. doi:10.1093/ajcp/aqaa112
  54. Lisboa Bastos M, Tavaziva G, Abidi SK, et al. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. BMJ. 2020;370:m2516. Published 2020 Jul 1. doi:10.1136/bmj.m2516
  55. Deeks JJ, Dinnes J, Takwoingi Y, et al. Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst Rev. 2020;6:CD013652. Published 2020 Jun 25. doi:10.1002/14651858.CD013652
  56. Weidner L, Gänsdorfer S, Unterweger S, et al. Quantification of SARS-CoV-2 antibodies with eight commercially available immunoassays [published online ahead of print, 2020 Jul 6]. J Clin Virol. 2020;129:104540. doi:10.1016/j.jcv.2020.104540
  57. Haselmann V, Kittel M, Gerhards C, et al. Comparison of test performance of commercial anti-SARS-CoV-2 immunoassays in serum and plasma samples [published online ahead of print, 2020 Jul 8]. Clin Chim Acta. 2020;S0009-8981(20)30323-5. doi:10.1016/j.cca.2020.07.007
  58. La Marca A, Capuzzo M, Paglia T, Roli L, Trenti T, Nelson SM. Testing for SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays [published online ahead of print, 2020 Jun 14]. Reprod Biomed Online. 2020;S1472-6483(20)30318-7. doi:10.1016/j.rbmo.2020.06.001
  59. Abe KT, Li Z, Samson R, Samavarchi-Tehrani P, Valcourt EJ, Wood H, Budylowski P, Dupuis A, Girardin RC, Rathod B, Colwill K. A simple protein-based SARS-CoV-2 surrogate neutralization assay. 2020 Jan 1.
  60. Favresse J, Eucher C, Elsen M, Marie TH, Dogné JM, Douxfils J, Bouge CS. Clinical performance of the Elecsys electrochemiluminescent immunoassay for the detection of SARS-CoV-2 total antibodies. Clinical Chemistry. 2020 Jun 2.
  61. Liu ZL, Liu Y, Wan LG, Xiang TX, Le AP, Liu P, Peiris M, Poon LL, Zhang W. Antibody profiles in mild and severe cases of COVID-19. Clinical chemistry. 2020 Jun 10.
  62. Naides SJ. Correctly Interpreting SARS-CoV-2 Serologic Assays. Clinical Chemistry. 2020 Jul 17.
  63. Gronowski AM, Farnsworth CW. In Reply: Correctly Interpreting SARS-CoV-2 Serologic Assays. Clinical Chemistry. 2020 Jul 17.
  64. Paiva KJ, Grisson RD, Chan PA, et al. Validation and Performance Comparison of Three SARS-CoV-2 Antibody Assays [published online ahead of print, 2020 Jul 25]. J Med Virol. 2020;1002/jmv.26341. doi:10.1002/jmv.26341
  65. Zhang C, Lin L, Tang D, et al. Antibody responses to SARS-CoV-2 in healthy individuals returning to Shenzhen [published online ahead of print, 2020 Jul 25]. J Med Virol. 2020;1002/jmv.26355. doi:10.1002/jmv.26355
  66. Pancrazzi A, Magliocca P, Lorubbio M, et al. Comparison of serologic and molecular SARS-CoV 2 results in a large cohort in Southern Tuscany demonstrates a role for serologic testing to increase diagnostic sensitivity [published online ahead of print, 2020 Jul 20]. Clin Biochem. 2020;S0009-9120(20)30791-8. doi:10.1016/j.clinbiochem.2020.07.002
  67. Gruer L, Bhopal R. Rapid roll out of SARS-CoV-2 antibody testing: even at high levels of specificity, an important proportion of test results will be false positives. BMJ. 2020;370:m2910. Published 2020 Jul 22. doi:10.1136/bmj.m2910
  68. Havers FP, Reed C, Lim T, et al. Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020 [published online ahead of print, 2020 Jul 21]. JAMA Intern Med. 2020;10.1001/jamainternmed.2020.4130. doi:10.1001/jamainternmed.2020.4130
  69. Larremore DB, Bubar KM, Grad YH. Implications of test characteristics and population seroprevalence on 'immune passport' strategies [published online ahead of print, 2020 Jul 20]. Clin Infect Dis. 2020;ciaa1019. doi:10.1093/cid/ciaa1019

 

Additional Resources Related to Testing:

Food & Drug Administration (FDA): FAQs on Diagnostic Testing for COVID-19 (Recently Updated with Guidance for Serology Testing)

John Hopkin’s Center for Health Security: Serology Testing for COVID-19

WHO: Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases

Public Health Laboratory Network:  Statement on Point-of-Care Serology Testing for SARS-CoV-2

Public Health England: Evaluation of Roche Elecsys AntiSARS-CoV-2 serology assay for the detection of anti-SARS-CoV-2 antibodies

Royal College of Pathologists: Recommendations for verification and validation methodology and sample sets for evaluation of assays for SARS-CoV-2 (COVID-19)

 

 

 

 ____________________________________________________________________

 

4. Biosafety Guidelines for the Clinical Laboratory

It is of the utmost importance that proper biosafety guidelines are followed by clinical laboratories when handling samples from suspected COVID-19 patients. The IFCC TF on COVID-19 recently published recommendations for biosafety measures for preventing infection from COVID-19 in clinical laboratories accessible at the following link. Key summary recommendations are listed below:

How can biosafety measures be implemented in clinical chemistry laboratories during the COVID-19 pandemic?

1a. Laboratories should adopt social distancing measures within the workplace as much as possible and feasible.

1b. The potential exposure and health status of the laboratory personnel is monitored daily.

What personal hygiene and personal protective equipment (PPE) should be used in clinical chemistry laboratories during the COVID-19 pandemic?

2a. Laboratory professionals must adhere rigorously to universally recommended standard precautions (i.e. frequent hand washing for at least 40 s with soap and water, or hand sanitizer when there is no access to handwashing, and to avoid touching the face) to minimize the risk of exposure to the virus.

2b. Laboratory professionals must wear standard laboratory PPE (i.e. masks and gloves, laboratory coat or gown, and eye protection) at all times.

2c. Laboratory professionals should wear preferably an N95 mask while engaged in aerosol-generating procedures on all non-centrifuged samples potentially containing vital SARS-CoV-2 particles.

How should laboratory staff handle routine patient specimens during the COVID-19 pandemic?

3a. For routine testing of blood, urine and body fluids, laboratories should use automated instruments and analyzers with closed preanalytical robotics, where possible.

3b. When manually handling non-respiratory specimens, aerosol-generating non-centrifuged sample processing steps should be carried out in a BSL2 cabinet, wearing the recommended PPE.

3c. The specimens should be sealed immediately after testing. High-risk specimens should be promptly disinfected or autoclaved.

3d. If there are no accidents, wait for more than 10 min for further processing after centrifugation stops. When the specimen suspected of COVID-19 is centrifuged, the operator must not leave the centrifuge. If an accident is suspected, or in some way the centrifugation is abnormal, stop the centrifugation. After replacing the biosafety level 3 protection equipment, stop centrifugation for more than 30 min, carefully open the lid, and spray and sterilize with 75% ethanol or other disinfectants. Take out the centrifuge rotor with blood collection tubes and then put them in the biosafety cabinet to treat.

How should staff decontaminate laboratory equipment and surfaces during the COVID-19 pandemic?

4a. Laboratory staff should decontaminate working surfaces with standard disinfectants approved for SARS-CoV-2 infections. The frequency shall be decided on local basis according to the volume of work, but shall not be basically less frequent than every 3 h.

4b. If a sample positive for SARS-CoV-2 is suspected of being leaked or contaminates the biosafety cabinet and bench and causes limited pollution: use a disinfectant with an effective chlorine content of 5500 mg/L for disinfection for more than 30 min; the disinfectant must be prepared immediately and used within 24 h. If positive specimens cause laboratory contamination: keep the laboratory space closed to prevent access by unauthorized personnel and to prevent the spread of pollutants. Cover the contaminated area with a towel containing 5500 mg/L of effective chlorine disinfectant and disinfect for more than 30 min. Peracetic acid (2 g/m3) or other disinfectants (3% H2O2, 100 mg/L chlorine dioxide, etc.) can be used to fumigate the laboratory overnight or disinfectant aerosol can be sprayed for 1–2 h.

In addition, interim guidelines from the World Health Organization on laboratory biosafety guidance related to coronavirus disease were updated on March 19th, 2020. 

Click here for a full list of WHO suggested decontaminants and here for a full list of EPA suggested decontaminants.

 

Efficacy of Masking: The efficacy and necessity of surgical grade or N95 masks in the clinical laboratory and the general public has not been well defined. In a recent paper in Nature Medicine by Leung and colleagues, surgical face masks were shown to significantly reduce the detection of influenza virus RNA in respiratory droplets and coronavirus RNA in aerosols, with a trend toward reduced detection of coronavirus RNA in respiratory droplets. In light of increasing evidence towards the efficacy of masking, the WHO has reversed its initial recommendation and now supports government initiatives that require or encourage the public wearing of masks, marking a major shift. The CDC has also encouraged general masking, highlighting the importance of masking for all healthcare workers whether patient-facing or not.

COVID-19 Detection in Different Clinical Specimens: An important consideration in biosafety is the detectability of COVID-19 in clinical specimens. A recent JAMA article investigated biodistribution among different clinical specimens of inpatients with COVID-19. Study findings are summarized below:

COVID-19 Detection in Domestic Animals: A recent publication in Science investigated the susceptibility of domestic animals, including dogs, cats, chickens, pigs, and ducks. Their findings demonstrated that cats are susceptible to airborne infection while COVID-19 replicates poorly in dogs, pigs, chickens, and dogs. Healthcare workers should keep this in mind when interacting with domestic pets.

 

Additional biosafety resources/publications from other associations include:

Center for Disease Control: Biosafety Frequently Asked Questions

Center for Disease Control: Guidance for Use of Pneumatic Tube Systems for Transport of Respiratory Specimens from Suspected or Confirmed COVID-19 Patients

Health Canada: COVID-19 BioSafety Advisory

Pan American Health Organization: Requirements and technical specifications of personal protective equipment (PPE) in healthcare

Public Health England: Safe handling and processing for COVID-19 samples in laboratories

NSW Clinical Excellence Commission: Application of PPE in Response to COVID-19 Pandemic

 

Key Publications on Biosafety: 

  1. Lippi G, Adeli K, Ferrari M, Horvath AR, Koch D, Sethi S, Wang CB. Biosafety measures for preventing infection from COVID-19 in clinical laboratories: IFCC Taskforce Recommendations. Clinical Chemistry and Laboratory Medicine (CCLM). 2020 May 12;1(ahead-of-print). PMID: 32396137
  2. Chang D, Xu H, Rebaza A, Sharma L, Cruz CS. Protecting health-care workers from subclinical coronavirus infection. The Lancet Respiratory Medicine. 2020 Mar 1;8(3):e13. PMID: 32061333
  3. Yeo C, Kaushal S, Yeo D. Enteric involvement of coronaviruses: is faecal–oral transmission of SARS-CoV-2 possible?. The Lancet Gastroenterology & Hepatology. 2020 Apr 1;5(4):335-7. PMID: 32087098
  4. Chin A, Chu J, Perera M, Hui K, Yen HL, Chan M, Peiris M, Poon L. Stability of SARS-CoV-2 in different environmental conditions. 2020 Jan 1.
  5. Klompas M, Morris CA, Sinclair J, Pearson M, Shenoy ES. Universal Masking in Hospitals in the Covid-19 Era. New England Journal of Medicine. 2020 Apr 1. PMID: 32237672
  6. van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, Tamin A, Harcourt JL, Thornburg NJ, Gerber SI, Lloyd-Smith JO. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. New England Journal of Medicine. 2020 Mar 17. PMID: 32182409
  7. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, Yu J, Kang M, Song Y, Xia J, Guo Q. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. New England Journal of Medicine. 2020 Mar 19;382(12):1177-9. PMID: 32074444
  8. Leung NH, Chu DK, Shiu EY, Chan KH, McDevitt JJ, Hau BJ, Yen HL, Li Y, Ip DK, Peiris JM, Seto WH. Respiratory virus shedding in exhaled breath and efficacy of face masks. Nature Medicine. 2020 Apr 3:1-5.
  9. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, Niemeyer D, Jones TC, Vollmar P, Rothe C, Hoelscher M. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020 Apr 1:1-0. PMID: 32235945
  10. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, Tan W. Detection of SARS-CoV-2 in different types of clinical specimens. Jama. 2020 Mar 11. PMID: 32159775
  11. Shi J, Wen Z, Zhong G, Yang H, Wang C, Huang B, Liu R, He X, Shuai L, Sun Z, Zhao Y. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2. Science. 2020 Apr 8. PMID: 32269068
  12. Zheng S, Fan J, Yu F, Feng B, Lou B, Zou Q, Xie G, Lin S, Wang R, Yang X, Chen W. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. bmj. 2020 Apr 21;369. PMID: 32317267
  13. Sunjaya AP, Jenkins C. Rationale for universal face masks in public against COVID-19. Respirology.2020 Apr 30;10.1111. PMID: 32353901
  14. Somsen GA, van Rijn C, Kooij S, Bem RA, Bonn D. Small droplet aerosols in poorly ventilated spaces and SARS-CoV-2 transmission. Lancet Respir Med. 2020 May 27:S2213-2600(20)30245-9. doi: 10.1016/S2213-2600(20)30245-9. Epub ahead of print. PMID: 32473123.
  15. Bain W, Lee JS, Watson AM, Stitt-Fischer MS. Practical Guidelines for Collection, Manipulation and Inactivation of SARS-CoV-2 and COVID-19 Clinical Specimens. Curr Protoc Cytom. 2020 Jun;93(1):e77. doi: 10.1002/cpcy.77. PMID: 32502333.
  16. IGI Testing Consortium. Blueprint for a pop-up SARS-CoV-2 testing lab. Nat Biotechnol. 2020 Jun 18. doi: 10.1038/s41587-020-0583-3. Epub ahead of print. PMID: 32555529.

_____________________________________________________________________ 

 

 

5. Biochemical Monitoring of COVID-19 Patients:

The essential role of clinical laboratories in this pandemic extends beyond etiological diagnosis of COVID-19. Biochemical monitoring of COVID-19 patients through in vitro diagnostic testing is critical for assessing disease severity and progression as well as monitoring therapeutic intervention. Several common in vitro diagnostic tests have been implicated in unfavorable COVID-19 progression, potentially providing important prognostic information. A recommended test list based on current literature is included below along with the major laboratory abnormalities associated with adult COVID-19 patients and their potential clinical indications (1-17). In addition to more common laboratory tests, new evidence suggests that patients with severe COVID-19 could be at risk for cytokine storm syndrome. Cytokine tests, particularly IL-6, should be used where possible to assess severe patients suspected of hyperinflammation (7,9).

 

Special considerations for pediatrics: Importantly, unlike adults, the laboratory profile in severe COVID-19 pediatric patients is not clear and does not appear to be consistent with SARS. A recent publication recommends clinicians monitor lymphocyte count, c-reactive protein, and procalcitonin to assess severe infection. IL-6 should also be investigated as a potential pediatric prognostic indicator (2). A preliminary description of pediatric U.S. COVID-19 cases was published by the CDC on April 10th, 2020. In line with data from China, the CDC reports that pediatric COVID-19 cases might be less severe when compared to adults and that children may experience different symptoms. Specifically, positive pediatric patients were reported to not always be associated with fever or cough as reported signs and symptoms.  Additionally, although most cases reported among children to date have not been severe, the CDC recommends clinicians maintain a high index of suspicion for COVID-19 infection in children and monitor for progression of illness, particularly among infants and children with underlying conditions. Importantly, interpretation of pediatric laboratory tests based on known adult trends is not recommended due to lack of pediatric information and characteristics. Recent data also suggests a new phenomenon affecting previously asymptomatic children with SARS-CoV-2 infection manifesting as a hyperinflammatory syndrome with multiorgan involvement similar to Kawasaki disease shock syndrome. Further research into the pediatric manifestations of COVID-19 is essential.

Special considerations for pregnant women during COVID-19 pandemic: Researchers have reported potential vertical transmission of COVID-19 in China (19, 20). Thus, minimizing the risk transmission and viral exposure to pregnant women is incredibly important. Many labs have implemented modifications for the required Gestational Diabetes Mellitus screening, including:

Key Publications on Biochemical Monitoring: 

General

  1. Henry BM, de Oliveira MH, Benoit S, Plebani M, Lippi G.Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clinical Chemistry and Laboratory Medicine (CCLM). 2020 Apr 10;1(ahead-of-print). PMID:32286245
  2. Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clinical Chemistry and Laboratory Medicine (CCLM). 2020 Mar 3. PMID:32119647
  3. Lippi G, Plebani M. The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks. Clinical Chemistry and Laboratory Medicine (CCLM). 2020 Mar 19. PMID:32191623
  4. Gao Y, Li T, Han M, Li X, Wu D, Xu Y, Zhu Y, Liu Y, Wang X, Wang L. Diagnostic Utility of Clinical Laboratory Data Determinations for Patients with the Severe COVID‐ Journal of Medical Virology. 2020 Mar 17. PMID: 32181911
  5. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP, Alvarado-Arnez LE, Bonilla-Aldana DK, Franco-Paredes C, Henao-Martinez AF, Paniz-Mondolfi A. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Medicine and Infectious Disease. 2020 Mar 13:101623. PMID: 32179124
  6. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Medicine. 2020 Mar 3:1-3. PMID:32125452
  7. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020 Mar 11. PMID:32171076
  8. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DS, Du B. Clinical characteristics of coronavirus disease 2019 in China. New England Journal of Medicine. 2020 Feb 28. PMID: 32109013
  9.  Kavsak PA, de Wit K, Worster A. Clinical chemistry tests for patients with COVID-19–important caveats for interpretation. Clinical Chemistry and Laboratory Medicine (CCLM). 2020 Apr 16;1(ahead-of-print). PMID: 32301748
  10. Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, Wang Z, Li J, Li J, Feng C, Zhang Z. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Science China Life Sciences. 2020 Mar;63(3):364-74. PMID:32048163
  11. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB.Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020 Apr 13.PMID:32282022
  12. Ferrari D, Motta A, Strollo M, Banfi G, Locatelli M. Routine blood tests as a potential diagnostic tool for COVID-19. Clinical Chemistry and Laboratory Medicine (CCLM). 2020 Apr 16;1(ahead-of-print). PMID: 32301746
  13. Lippi G, South AM, Henry BM. ANNALS EXPRESS: Electrolyte Imbalances in Patients with Severe Coronavirus Disease 2019 (COVID-19. Ann Clin Biochem. 2020 Apr 8 (ahead-of-print). PMID: 32266828
  14. Nichols JH, Rauch CA. A Laboratory Risk Assessment during the Coronavirus (COVID-19) Pandemic. The Journal of Applied Laboratory Medicine. 2020 Apr 16. PMCID: PMC7184397
  15. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, Barnaby DP, Becker LB, Chelico JD, Cohen SL, Cookingham J. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020 Apr 22. PMID: 32320003
  16. Kavsak PA, de Wit K, Worster A. Emerging key laboratory tests for patients with COVID-19. Clinical Biochemistry. 2020 Apr 30. PMID: 32360478
  17. Lu G, Wang J. Dynamic changes in routine blood parameters of a severe COVID-19 case. Clinica Chimica Acta. 2020 May 13. PMID: 32405079
  18. Zhu L, She ZG, Cheng X, Qin JJ, Zhang XJ, Cai J, Lei F, Wang H, Xie J, Wang W, Li H, Zhang P, Song X, Chen X, Xiang M, Zhang C, Bai L, Xiang D, Chen MM, Liu Y, Yan Y, Liu M, Mao W, Zou J, Liu L, Chen G, Luo P, Xiao B, Zhang C, Zhang Z, Lu Z, Wang J, Lu H, Xia X, Wang D, Liao X, Peng G, Ye P, Yang J, Yuan Y, Huang X, Guo J, Zhang BH, Li H. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab. 2020 Jun 2;31(6):1068-1077.e3. doi: 10.1016/j.cmet.2020.04.021. Epub 2020 May 1. PMID: 32369736

Inflammatory Markers:

  1. Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis. Clinica chimica acta; international journal of clinical chemistry. 2020 Mar 4. PMID:32145275
  2. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet. 2020 Mar 16. PMID:32192578
  3. Monteleone G, Sarzi-Puttini PC, Ardizzone S. Preventing COVID-19-induced pneumonia with anticytokine therapy. The Lancet Rheumatology. 2020 Apr 6. PMID: TBD
  4. McGonagle D, Sharif K, O'Regan A, Bridgewood C. Interleukin-6 use in COVID-19 pneumonia related macrophage activation syndrome. Autoimmunity Reviews. 2020 Apr 3:102537. PMID: 32251717
  5. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. Jama. 2020 Mar 17;323(11):1061-9. PMID: 32031570
  6. Chen X, Zhao B, Qu Y, Chen Y, Xiong J, Feng Y, Men D, Huang Q, Liu Y, Yang B, Ding J. Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients. Clinical Infectious Diseases. 2020 Apr 17. PMID: 32301997
  7. Zhao Y, Qin L, Zhang P, Li K, Liang L, Sun J, Xu B, Dai Y, Li X, Zhang C, Peng Y. Longitudinal Profiling of Cytokines and Chemokines in COVID-19 Reveals Inhibitory Mediators IL-1Ra and IL-10 Are Associated with Disease Severity While Elevated RANTES Is an Early Predictor of Mild Disease. Non-peer reviewed preprint.
  8. Liu F, Li L, Xu M, Wu J, Luo D, Zhu Y, Li B, Song X, Zhou X. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. Journal of Clinical Virology. 2020 Apr 14:104370. PMID: 32344321
  9. Aziz M, Fatima R, Assaly R. Elevated Interleukin‐6 and Severe COVID‐19: A Meta‐ Journal of Medical Virology. 2020 Apr 28. PMID: 32343429
  10. Lapić I, Rogić D, Plebani M. Erythrocyte sedimentation rate is associated with severe coronavirus disease 2019 (COVID-19): a pooled analysis. Clinical chemistry and laboratory medicine. 2020 May 9. PMID: 32386190
  11. Del Valle et al. An inflammatory cytokine signature helps predict COVID-19 severity and death. https://doi.org/10.1101/2020.05.28.20115758
  12. Ognibene A, Lorubbio M, Magliocca P, Tripodo E, Vaggelli G, Iannelli G, Feri M, Scala R, Tartaglia AP, Galano A, Pancrazzi A. ELEVATED MONOCYTE DISTRIBUTION WIDTH IN COVID-19 PATIENTS: THE CONTRIBUTION OF THE NOVEL SEPSIS INDICATOR. Clinica Chimica Acta. 2020 Jun 3. PMID: 32504637
  13. Chi Y, Ge Y, Wu B, Zhang W, Wu T, Wen T, Liu J, Guo X, Huang C, Jiao Y, Zhu F, Zhu B, Cui L. Serum Cytokine and Chemokine profile in Relation to the Severity of Coronavirus disease 2019 (COVID-19) in China. J Infect Dis. 2020 Jun 21:jiaa363. doi: 10.1093/infdis/jiaa363. Epub ahead of print. PMID: 32563194.
  14. Spectrum of innate and adaptive immune response to SARS CoV 2 infection across asymptomatic, mild and severe cases; a longitudinal cohort study. https://doi.org/10.1101/2020.06.22.20137141
  15. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, Hu JL, Xu W, Zhang Y, Lv FJ, Su K. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nature Medicine. 2020 Jun 18:1-5. https://doi.org/10.1038/s41591-020-0965-6
  16. Pfaar O, Torres MJ, Akdis CA. COVID-19: A series of important recent clinical and laboratory reports in immunology and pathogenesis of SARS-CoV-2 infection and care of allergy patients [published online ahead of print, 2020 Jun 26]. Allergy. 2020;10.1111/all.14472. doi:10.1111/all.14472
  17. Gupta A, Madhavan MV, Sehgal K, et al. Extrapulmonary manifestations of COVID-19 [published online ahead of print, 2020 Jul 10]. Nat Med. 2020;10.1038/s41591-020-0968-3. doi:10.1038/s41591-020-0968-3
  18. Rocio LG, Alberto UR, Paloma T, et al. Interleukin-6-based mortality risk model for hospitalised COVID-19 patients [published online ahead of print, 2020 Jul 22]. J Allergy Clin Immunol. 2020;S0091-6749(20)31027-7. doi:10.1016/j.jaci.2020.07.009

Cardiac Markers:

  1. Lippi G, Lavie CJ, Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis. Progress in cardiovascular diseases. 2020 Mar 10. PMID:32169400
  2. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, Wang H, Wan J, Wang X, Lu Z. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA cardiology. 2020 Mar 27. PMID: 32219356
  3. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nature Reviews Cardiology. 2020 Mar 5:1-2. PMID:32139904
  4. American College of Cardiology. Troponin and BNP Use in COVID-19. 28 Mar 2020.
  5. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, Gong W, Liu X, Liang J, Zhao Q, Huang H. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA cardiology. 2020 Mar 25. PMID: 32211816
  6. Chapman AR, Bularga A, Mills NL. High-Sensitivity Cardiac Troponin Can Be An Ally in the Fight Against COVID-19. Circulation. 2020 Apr 6. PMID: 32251612
  7. Shi S, Qin M, Cai Y, Liu T, Shen B, Yang F, Cao S, Liu X, Xiang Y, Zhao Q, Huang H. Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019. European Heart Journal. 2020 May 11. PMID: 32391877
  8. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood, The Journal of the American Society of Hematology. 2020 Jun 4;135(23):2033-40. PMID: 32339221
  9. Harmouch F, Shah K, Hippen J, Kumar A, Goel H. Is it all in the heart? Myocardial injury as major predictor of mortality among hospitalized COVID-19 patients [published online ahead of print, 2020 Jul 25]. J Med Virol. 2020;10.1002/jmv.26347. doi:10.1002/jmv.26347
  10. Deng P, Ke Z, Ying B, Qiao B, Yuan L. The diagnostic and prognostic role of myocardial injury biomarkers in hospitalized patients with COVID-19 [published online ahead of print, 2020 Jul 16]. Clin Chim Acta. 2020;510:186-190. doi:10.1016/j.cca.2020.07.018
  11. Qin JJ, Cheng X, Zhou F, et al. Redefining cardiac biomarkers in predicting mortality of inpatients with COVID-19 [published online ahead of print, 2020 Jul 14]. Hypertension. 2020;10.1161/HYPERTENSIONAHA.120.15528. doi:10.1161/HYPERTENSIONAHA.120.15528

Hematology Markers:

  1. Fan BE, Chong VC, Chan SS, Lim GH, Lim KG, Tan GB, Mucheli SS, Kuperan P, Ong KH. Hematologic parameters in patients with COVID-19 infection. American journal of hematology. 2020 Mar 4. PMID:32129508
  2. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clinica Chimica Acta. 2020 Mar 13. PMID:32178975
  3. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of Thrombosis and Haemostasis. 2020 Jan 1. PMID:32073213
  4. Han H, Yang L, Liu R, Liu F, Wu KL, Li J, Liu XH, Zhu CL. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clinical Chemistry and Laboratory Medicine (CCLM). 2020 Mar 16;1(ahead-of-print). PMID: 32172226
  5. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, Chen H, Ding X, Zhao H, Zhang H, Wang C. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. New England Journal of Medicine. 2020 Apr 8. PMID: 32268022
  6. Salamanna F, Maglio M, Landini MP, Fini M. Platelet functions and activities as potential hematologic parameters related to Coronavirus Disease 2019 (Covid-19). Platelets. 2020 May 12:1-6. PMID: 32397915
  7. Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. The Lancet Haematology. 2020 May 11. PMID: 32407672
  8. Al-Samkari H, Karp Leaf RS, Dzik WH, Carlson JC, Fogerty AE, Waheed A, Goodarzi K, Bendapudi P, Bornikova L, Gupta S, Leaf D, Kuter DJ, Rosovsky RP. COVID and Coagulation: Bleeding and Thrombotic Manifestations of SARS-CoV2 Infection. Blood. 2020 Jun 3:blood.2020006520. doi: 10.1182/blood.2020006520. Epub ahead of print. PMID: 32492712.
  9. Dewaele K, Claeys R. Hemophagocytic lymphohistiocytosis in SARS-CoV-2 infection. Blood. 2020 Jun 18;135(25):2323. doi: 10.1182/blood.2020006505. PMID: 32556137.

Hepatic & Renal Markers:

  1. Bangash MN, Patel J, Parekh D. COVID-19 and the liver: little cause for concern. The Lancet Gastroenterology & Hepatology. 2020 Mar 20. PMID: 32203680
  2. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, Li J, Yao Y, Ge S, Xu G. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney international. 2020 Mar 20. PMID: 32247631
  3. Fan Z, Chen L, Li J, Cheng X, Yang J, Tian C, Zhang Y, Huang S, Liu Z, Cheng J. Clinical features of COVID-19-related liver damage. Clinical Gastroenterology and Hepatology. 2020 Apr 10. PMID: 32283325
  4. Lax SF, Skok K, Zechner P, Kessler HH, Kaufmann N, Koelblinger C, Vander K, Bargfrieder U, Trauner M. Pulmonary arterial thrombosis in COVID-19 with fatal outcome: results from a prospective, single-center, clinicopathologic case series. Annals of Internal Medicine. 2020 May. PMID: 32422076
  5. Agarwal A, Chen A, Ravindran N, To C, Thuluvath PJ. Gastrointestinal and liver manifestations of COVID-19. Journal of Clinical and Experimental Hepatology. 2020 Apr 1. PMCID: PMC7212283
  6. Su H, Yang M, Wan C, Yi LX, Tang F, Zhu HY, Yi F, Yang HC, Fogo AB, Nie X, Zhang C. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney international. 2020 Apr 9. PMID: 32327202
  7. Portincasa P, Krawczyk M, Smyk W, Lammert F, Di Ciaula A. COVID-19 and nonalcoholic fatty liver disease: two intersecting pandemics [published online ahead of print, 2020 Jun 26]. Eur J Clin Invest. 2020;e13338. doi:10.1111/eci.13338
  8. Sun JK, Zhang WH, Zou L, et al. Serum calcium as a biomarker of clinical severity and prognosis in patients with coronavirus disease 2019 [published online ahead of print, 2020 Jun 25]. Aging (Albany NY). 2020;12:10.18632/aging.103526. doi:10.18632/aging.103526
  9. Bertolini A, van de Peppel IP, Bodewes FAJA, et al. Abnormal liver function tests in COVID-19 patients: relevance and potential pathogenesis [published online ahead of print, 2020 Jul 23]. Hepatology. 2020;10.1002/hep.31480. doi:10.1002/hep.31480
  10. Zarifian A, Bidary MZ, Arekhi S, et al. Gastrointestinal and hepatic abnormalities in patients with confirmed COVID-19: a systematic review and meta-analysis [published online ahead of print, 2020 Jul 18]. J Med Virol. 2020;10.1002/jmv.26314. doi:10.1002/jmv.26314
  11. Saad Alharbi K, Al-Abbasi FA, Prasad Agrawal G, Sharma A, Kowti R, Kazmi I. Impact of COVID-19 on Nephrology Patients: A Mechanistic Outlook for Pathogenesis of Acute Kidney Injury [published online ahead of print, 2020 Jul 15]. Altern Ther Health Med. 2020;AT6544.

Pediatrics:

  1. Henry BM, Lippi G, Plebani M. Laboratory abnormalities in children with novel coronavirus disease 2019. Clinical Chemistry and Laboratory Medicine (CCLM). 2020 Mar 16. PMID: 32172227
  2. Cao J, Devaraj S. COVID-19 in Pediatrics: A Laboratory Perspective. The Journal of Applied Laboratory Medicine. 2020 Apr 15.
  3. Xia W, Shao J, Guo Y, Peng X, Li Z, Hu D. Clinical and CT features in pediatric patients with COVID‐19 infection: Different points from adults. Pediatric pulmonology. 2020 Mar 5. PMID:32134205
  4. Pedersen SF, Ho YC. SARS-CoV-2: A Storm is Raging. The Journal of Clinical Investigation. 2020 Mar 27. PMID: 32217834
  5. Dong L, Tian J, He S, Zhu C, Wang J, Liu C, Yang J. Possible vertical transmission of SARS-CoV-2 from an infected mother to her newborn. Jama. 2020 Mar 26. PMID:32215581
  6. Zeng H, Xu C, Fan J, Tang Y, Deng Q, Zhang W, Long X. Antibodies in infants born to mothers with COVID-19 pneumonia. Jama. 2020 Mar 26. PMID: 32215589
  7. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, Li J, Zhao D, Xu D, Gong Q, Liao J. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. The Lancet. 2020 Mar 7;395(10226):809-15. PMID: 32151335
  8. Jiang S, Liu P, Xiong G, Yang Z, Wang M, Li Y, Yu XJ. Coinfection of SARS-CoV-2 and multiple respiratory pathogens in children. Clinical Chemistry and Laboratory Medicine (CCLM). 2020 Apr 16;1(ahead-of-print). PMID: 32301747
  9. Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, Zhang W, Wang Y, Bao S, Li Y, Wu C. SARS-CoV-2 infection in children. New England Journal of Medicine. 2020 Mar 18. PMID: 32187458
  10. Liu W, Wang J, Li W, Zhou Z, Liu S, Rong Z. Clinical characteristics of 19 neonates born to mothers with COVID-19. Frontiers of Medicine. 2020 Apr 13:1-6. PMID: 32285380
  11. Nathan N, Prevost B, Corvol H. Atypical presentation of COVID-19 in young infants. The Lancet. 2020 Apr 27. PMID: 32353326
  12. Zhang Y, Xu J, Jia R, et al. Protective humoral immunity in SARS-CoV-2 infected pediatric patients]. Cell Mol Immunol. 2020 May 7. PMID: 32382126
  13. Zimmermann P, Curtis N. COVID-19 in Children, Pregnancy and Neonates: A Review of Epidemiologic and Clinical Features. The Pediatric Infectious Disease Journal. 2020 Jun 1;39(6):469-77. PMID: 32398569
  14. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. The Lancet. 2020 May 7. PMID: 32386565
  15. Jones VG, Mills M, Suarez D, Hogan CA, Yeh D, Segal JB, Nguyen EL, Barsh GR, Maskatia S, Mathew R. COVID-19 and Kawasaki disease: novel virus and novel case. Hospital Pediatrics. 2020 May 1:hpeds-2020. PMID: 32265235
  16. Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. Hyperinflammatory shock in children during COVID-19 pandemic. The Lancet. 2020 May 7. PMID: 32386565
  17. DeBiasi RL, Song X, Delaney M, Bell M, Smith K, Pershad J, Ansusinha E, Hahn A, Hamdy R, Harik N, Hanisch B. Severe COVID-19 in children and young adults in the Washington, DC metropolitan region. The Journal of Pediatrics. 2020 May 13. PMID: 32405091
  18. Shekerdemian LS, Mahmood NR, Wolfe KK, Riggs BJ, Ross CE, McKiernan CA, Heidemann SM, Kleinman LC, Sen AI, Hall MW, Priestley MA. Characteristics and Outcomes of Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units. JAMA pediatrics. 2020 May 11. PMID: 32392288
  19. https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19
  20. Henry BM, Benoit SW, de Oliveira MH, Hsieh WC, Benoit J, Ballout RA, Plebani M, Lippi G. Laboratory Abnormalities in Children with Mild and Severe Coronavirus Disease 2019 (COVID-19): a pooled analysis and review. Clinical Biochemistry. 2020 May 27. PMID: 32473151
  21. Batu ED, Özen S. Implications of COVID-19 in pediatric rheumatology [published online ahead of print, 2020 Jun 4]. Rheumatol Int. 2020;10.1007/s00296-020-04612-6. doi:10.1007/s00296-020-04612-6. PMID: 32500409
  22. Colonna C, Spinelli F, Monzani NA, Ceriotti F, Gelmetti C. Chilblains in children in the time of Covid-19: new evidence with serology assay [published online ahead of print, 2020 Jun 13]. Pediatr Dermatol. 2020;1111/pde.14269. doi:10.1111/pde.14269
  23. Götzinger, Florian & Santiago García, Begoña & Noguera, Antoni & Lanaspa, Miguel & Carducci, Francesca & Gabrovska, Natalia & Velizarova, Svetlana & Prunk, Petra & Osterman, Veronika & Krivec, Uros & Vecchio, Andrea & Shingadia, Delane & Soriano-Arandes, Antoni & Melendo, Susana & Lanari, Marcello & Pierantoni, Luca & Wagner, Noémie & L'Huillier, Arnaud. (2020). COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. The Lancet Child & Adolescent Health. 10.1016/S2352-4642(20)30177-2.
  24. Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents [published online ahead of print, 2020 Jun 29]. N Engl J Med. 2020;NEJMoa2021680. doi:10.1056/NEJMoa2021680
  25. Kache S, Chisti MJ, Gumbo F, et al. COVID-19 PICU guidelines: for high- and limited-resource settings [published online ahead of print, 2020 Jul 7]. Pediatr Res. 2020;10.1038/s41390-020-1053-9. doi:10.1038/s41390-020-1053-9
  26. Moraleda C, Serna-Pascual M, Soriano-Arandes A, et al. Multi-Inflammatory Syndrome in Children related to SARS-CoV-2 in Spain [published online ahead of print, 2020 Jul 25]. Clin Infect Dis. 2020;ciaa1042. doi:10.1093/cid/ciaa1042
  27. Henderson LA, Canna SW, Friedman KG, et al. American College of Rheumatology Clinical Guidance for Pediatric Patients with Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARS-CoV-2 and Hyperinflammation in COVID-19. Version 1 [published online ahead of print, 2020 Jul 23]. Arthritis Rheumatol. 2020;10.1002/art.41454. doi:10.1002/art.41454
  28. Lee PY, Day-Lewis M, Henderson LA, et al. Distinct clinical and immunological features of SARS-COV-2-induced multisystem inflammatory syndrome in children [published online ahead of print, 2020 Jul 23]. J Clin Invest. 2020;141113. doi:10.1172/JCI141113

 

Maternal:

  1. Poon LC, Yang H, Kapur A, Melamed N, Dao B, Divakar H, McIntyre HD, Kihara AB, Ayres‐de‐Campos D, Ferrazzi EM, Di Renzo GC. Global interim guidance on coronavirus disease 2019 (COVID‐19) during pregnancy and puerperium from FIGO and allied partners: Information for healthcare professionals. International Journal of Gynecology & Obstetrics. 2020 Apr 4. PMID: 32248521
  2. Mullins E, Evans D, Viner RM, O'Brien P, Morris E. Coronavirus in pregnancy and delivery: rapid review. Ultrasound in Obstetrics & Gynecology. 2020 Mar 17. PMID: 32180292
  3. Summary of guidelines related to obstetrics and gynaecology published by the ObG Project.  Coronavirus and Pregnancy: CDC Guidance and Professional Recommendations
  4. Golden TN, Simmons RA. Maternal and Neonatal Response to COVID-19 [published online ahead of print, 2020 Jun 23]. Am J Physiol Endocrinol Metab. 2020;1152/ajpendo.00287.2020. doi:10.1152/ajpendo.00287.2020
  5. Molina LP, Chow SK, Nickel A, Love JE. Prolonged Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) RNA in an Obstetric Patient With Antibody Seroconversion [published online ahead of print, 2020 Jul 21]. Obstet Gynecol. 2020;10.1097/AOG.0000000000004086. doi:10.1097/AOG.0000000000004086
  6. Barbero P, Mugüerza L, Herraiz I, et al. SARS-CoV-2 in pregnancy: characteristics and outcomes of hospitalized and non-hospitalized women due to COVID-19 [published online ahead of print, 2020 Jul 20]. J Matern Fetal Neonatal Med. 2020;1-7. doi:10.1080/14767058.2020.1793320
  7. Ashraf MA, Keshavarz P, Hosseinpour P, et al. Coronavirus Disease 2019 (COVID-19): A Systematic Review of Pregnancy and the Possibility of Vertical Transmission. J Reprod Infertil. 2020;21(3):157-168.
  8. Takemoto MLS, Menezes MO, Andreucci CB, et al. Maternal mortality and COVID-19 [published online ahead of print, 2020 Jul 16]. J Matern Fetal Neonatal Med. 2020;1-7. doi:10.1080/14767058.2020.1786056

 _____________________________________________________________________

6. Other Educational Materials & Webinars

Webinar on COVID-19 – Approach to Laboratory Testing and Biosafety - Cosponsored by the Canadian Society of Clinical Chemists (CSCC) and Roche Canada
Moderator: Dr. David Kinniburgh (CA)
Speakers: Prof Giuseppe Lippi (IT); Prof Khosrow Adeli (CA).

 

TransAsia Webinar on COVID-19 – Challenges in Laboratory Investigations and Clinical Management - Cosponsored by: IFCC EMD and Transasia Erba Mannheim
Speakers: Prof. Nader Rifai (US); Professor Mark Berg (US); Professor Leo Poon (HK).

 

Free Course on COVID-19 from AACC Learning Lab: AACC developed this content with leading scientists as part of AACC Learning Lab on NEJM Knowledge+. The free course covers COVID-19 transmission, complications, diagnosis, and more.

Free AACC Laboratory Pearl on COVID-19: The Pearl by Dr. Lippi reveals potential origins for the virus, how it attacks the body, its symptoms, and associated laboratory abnormalities.

Free AACC Clinical Chemistry Podcast - Why Clinical Labs Are Essential to Containing COVID-19: Dr. Matthew Binnicker gives an update on the coronavirus outbreak and discusses what is needed to bring this global epidemic under control.

Free AACC Clinical Chemistry Podcast - Molecular Diagnosis of a Novel Coronavirus: Dr. Leo Poon of the University of Hong Kong gives expert insight into the 2019 novel coronavirus, and discusses the new molecular diagnostic assays his team has developed to detect and quantify this virus.

Roche-Sponsored COVID-19 Online Education Program: Featuring three presentations and the live roundtable discussion, the upcoming edition is set to provide you with important information on the role of each of the tests to control the pandemic (Streaming June 2 2020).

Science Webinar: Coronavirus - A survival guide

Science Webinar: Monitoring the immune system to fight COVID-19: CD4 status, lymphopenia, and infectivity

Siemens Healthineers COVID-19 Testing Guide: A new COVID-19 Laboratory Testing Guide from Siemens Healthineers provides essential information for clinicians to help manage each stage of COVID-19 patient care: diagnosis, prognosis, therapy and follow-up.

CAP Webinar: Navigating Implementation of SARS-CoV-2 Testing in Your Laboratory

_____________________________________________________________________

7. Big Data Tools in COVID-19

Datasets:

  1. COVID-19 Open Research Dataset (CORD-19): A freely available, downloadable and updated weekly collection of publications (many as full text) on COVID-19, SARS-CoV-2, and related coronaviruses
  2. World Health Organization: Global research on coronavirus disease (COVID-19) Registry 
  3. LITCOVID: National Institutes of Health and the National Library of Medicine aggregation of COVID-19 general information and news. 
  4. Centers for Disease Control and Prevention COVID-19 Research Articles Downloadable Database: The Stephen B. Thacker CDC Library is collecting COVID-19 research articles and compiling them into an easily accessible and downloadable database to help researchers find the latest COVID-19 research
  5. COVIDView: A Weekly Surveillance Summary of U.S. COVID-19 Activity provided by the Centers for Disease Control and Prevention. 
  6. Mark Tech Post: COVID-19 resources for machine learning and data science research (lists 29 different datasets)
  7. Larson T, Culbreath K, Chavez D, Larson R, Crossey M, Grenache DG. Modeling SARS-CoV-2 positivity using laboratory data: timing is everything. Clinical Chemistry. 2020 Apr 30. PMID: 32353116

 

Machine learning tools:

  1. WELL AI: COVID-19 Machine Learning Analytics for Researchers 
  2. SciSight: SciSight is a tool for exploring associations between concepts appearing in the COVID-19 Open Research Dataset.

Disclaimer: This collection of resources on this webpage reflects a rapidly changing situation and due to the need for quick answers during the COVID-19 pandemic, we acknowledge that most fast-tracked publications are based on observations, often on a small number of cases, which would be considered as preliminary evidence. The IFCC Task Force has not critically appraised all resources cited here for scientific validity but tried to present information that is believed to help laboratory professionals in formulating their local policies in a more informed manner. The interim advice or conclusions presented here may change as more information is gathered.
]]> New Documents in Spanish in RIA2020-07-22T09:45:15Z /ifcc-news/2020-07-21-new-documents-in-spanish-in-ria/ IFCC Office  

La metrología y sus herramientas aplicables a la bioquímica y medicina del laboratorio

Dr. Raúl Girardi, Chair Working Group Ibero-american Nomenclature and Translations - WG-IANT/RIA/CPD-IFCC.
Director Revista Diagnóstico in Vitro

La metrología es la ciencia de las mediciones y sus aplicaciones, incluye los aspectos teóricos y prácticos de la medición. Como tal, es aquella rama de las ciencias que se ocupa de las mediciones de los sistemas de unidades y de los instrumentos usados para efectuarlas e implementarlas.

♦ ♦ ♦ ♦ ♦

 

Codificación de Pruebas de Laboratorio con Nomenclatura Sistemática en Español

Dr Félix Gascón Luna,Responsable funcional MPA y GNC
Director UGC Laboratorio Clínico ASNC Hospital "Valle de los Pedroches", Pozoblanco Córdoba - España

La base de datos de pruebas de laboratorio del GNC nace con la finalidad de facilitar el intercambio de información entre los Sistemas de Información de los Laboratorios (SIL) y la historia clínica electrónica. Su objetivo es servir de lenguaje común para el intercambio de información, con independencia del lenguaje “local” de cada laboratorio.

 

Haga clic en los títulos para descargar el documento

Para otros documentos en español, visite: https://www.ifcc.org/ria/documentos/

 

]]> IFCC eNews No 7/8 Jul/Aug 20202020-07-10T08:00:22Z /ifcc-news/2020-07-09-ifcc-enews-no-78-julaug-2020/ IFCC Office

IFCC eNews: July -August 2020
eNews logo large globe eNews flipping
PDF version
 Flip-page version
                                                           Note for eMagStudio publications: the type-in fields for the "Search" and "Go to page" functions are not enabled in full-screen mode.

 

IN THIS ISSUE:

  • EDITORIAL
    • Message from the eNews editor
  • THE VOICE OF IFCC
    • Message from the IFCC President
    • Coming Together in Social Media to Honour Medical Lab Professionals Fighting COVID-19
    • Social distancing and the truth of masks
    • Renaming the IFCC Distinguished Clinical Chemist Award ~ Howard Morris Distinguished Clinical Chemist Award ~
    • Extending IFCC in social media
    • Igniting the AI and e-health creative sparks at APFCB Jaipur (IN)
  • IFCC: THE YOUNG SCIENTISTS
    • Video promoting contribution of laboratory medicine professionals during COVID-19 pandemic
  • CONTRIBUTE TO IFCC eNEWS
    • Recognizing valued advocates of the UNIVANTS of Healthcare Excellence Programme
  • NEWS FROM REGIONAL FEDERATIONS AND MEMBER SOCIETIES
    • News from Pakistan
  • IFCC'S CALENDAR OF CONGRESSES, CONFERENCES
    • Calendar of IFCC Congresses/Conferences and Regional Federations' Congresses
    • Calendar of events with IFCC auspices
]]> The IFCC is happy to announce the first Spanish version of AACC COVID-19 Pearl of Laboratory Medicine2020-07-02T13:36:34Z /ifcc-news/2020-06-30-aacc-covid-19-first-pearl-of-laboratory-medicine-cápsulas-en-español/ IFCC Office  

Para acceder a la Cápsula en Español, haga clic en el enlace - to access the Pearl click on the link: 

https://www.aacc.org/clinical-chemistry-trainee-council/trainee-council-in-spanish/pearls-of-laboratory-medicine/spanish-pearls/enfermedad-por-coronavirus-2019

El texto y las diapositivas se pueden descargar como archivos pdf - Text and slides can be downloaded as pdf files

]]> Diagnóstico in Vitro - Junio 20202020-06-29T12:58:27Z /ifcc-news/2020-06-29-div-junio-2020/ IFCC Office Auspiciado por la Federación Internacional de Química Clínica, "Diagnóstico in Vitro" es un nexo de unión entre los países Latinoamericanos, Portugal y España, que contribuye a difundir temas científicos a través de Internet, facilitando el conocimiento de publicaciones y temas de interés comunes a las ciencias del laboratorio clínico.

Número Junio 2020
Cover PDF.jpg Cover Flip.jpg

Click here to access the PDF version
Clic aquí para acceder la versión PDF

Click here to access the Flip version
Clic aquí para acceder la versión Flip

 

]]> New IFCC Executive Board 2021 - 20232020-06-22T16:46:59Z /ifcc-news/2020-06-19-new-ifcc-executive-board-2021-2023/ IFCC Office  

President                                                       Khosrow Adeli (Canada)*
Past President                                                   Maurizio Ferrari (Italy) **
Secretary                                                        David Kinniburgh (Canada)
Treasurer                                                        Alexander Haliassos (Greece)
African Regional Representative                    Adekunle Bashiru Okesina (Nigeria)
Asian Pacific Regional Representative          Sunil Sethi (Singapore)
Arab Federation Regional Representative     Abderrazek Hedhili (Tunisia)
European Regional Representative               Ana Maria Šimundić (Croatia)
Latin American Regional Representative       Ana Maria Lena Rodríguez (Uruguay)
North American Regional Representative      Stephen Hill (Canada)
Corporate Member Representative                Joseph Passarelli (Roche Diagnostics)

 

⋆ Prof Adeli became President in May 2020  

** Prof Ferrari will end his term in December 2020

For the current EB 2020, click here. 

]]> IFCC Annual Report 20192020-06-17T11:22:10Z /ifcc-news/2020-06-17-ifcc-annual-report-2019/ IFCC Office IFCC Annual Report 2019

In the IFCC Annual report, you will find reports from IFCC Officers on key projects covering a wide range of clinical, scientific, educational, and communication-related topics. National or Area Societies and Regional Federation reports are also included, allowing the opportunity to communicate their activities to other members.

 

Click on the image to download your copy

]]> IFCC eNews No 6 June 20202020-07-10T07:44:48Z /ifcc-news/2020-06-09-ifcc-enews-no-6-jun-2020/ IFCC Office

IFCC eNews: June 2020
eNews logo large globe eNews flipping
PDF version
 Flip-page version
                                                           Note for eMagStudio publications: the type-in fields for the "Search" and "Go to page" functions are not enabled in full-screen mode.

 

IN THIS ISSUE:

  • EDITORIAL
    • Message from the eNews editor
    • The IFCC is pleased to announce its new President: prof. Khosrow Adeli
  • THE VOICE OF IFCC
    • Message from the IFCC President
    • Critical role of laboratory medicine in the global response to the COVID-19 pandemic 7
    • The new IFCC Task Force on COVID-19 10
    • Highlights from recent events in bioethics: notes for better visualizing Task Force of Ethics collaborations
    • IFCC: Educational webinars on COVID-19 12
    • Igniting the AI and e-health creative sparks at APFCB Jaipur (IN)
  • IFCC: THE PEOPLE
    • Election of the IFCC Executive Board: reflections on the procedure
    • Welcome and thanks to the Chairs
  • IFCC: THE YOUNG SCIENTISTS
    • Mentorship interview: Prof Sharma and Dr Mitra
  • CONTRIBUTE TO IFCC eNEWS
    • Ethical digital technologies to flatten the curve
    • Standardization vs personalization for improved healthcare
  • NEWS FROM REGIONAL FEDERATIONS AND MEMBER SOCIETIES
    • News from Saudi Arabia
    • News from the Spanish Society of Laboratory Medicine (SEQCML)
    • News from EFLM functional units and updates on EFLM publications
  • IFCC WELCOMES TWO NEW MEMBERS
    • New full member: Iraqi Society of Molecular Biology and Genetics (ISMBG)
    • New affiliate member: The Order of Biochemists, Biologists and Chemists in the Healthcare System from Romania (OBBCHSR)
  • IFCC'S CALENDAR OF CONGRESSES, CONFERENCES
    • Calendar of IFCC Congresses/Conferences and Regional Federations' Congresses
    • Calendar of events with IFCC auspices
]]> eJIFCC Vol 31 n° 22020-06-02T11:18:13Z /ifcc-news/2020-06-02-ejifcc-vol-31-n-2/ IFCC Office  

eJIFCC Volume 31 no 2 - 2020
 
 
eJIFCC New 2015 Thumb for web.jpg
Click here to download a PDF of the full issue.
 
1 COVID-19: Armageddon before light?
Damien Gruson, Gabriel Ko, David Luu
2 Artificial Intelligence – powered search tools and resources in the fight against COVID-19
Larry J. Kricka, Sergei. Polevikov, Jason Y. Park, Paolo Fortina, Sergio Bernardini, Daniel Satchkov, Valentin Kolesov, Maxim Grishkov
3 Reference value for serum zinc level of adult population in Bangladesh
Nilima Barman, Marium Salwa, Debabrata Ghosh, Muhammed Waliur Rahman, Md. Nasir Uddin, M. Atiqul Haque
4 Blood lead levels in rag-pickers of Kathmandu and its association with hematological and biochemical parameters
Keyoor Gautam, Vivek Pant, Santosh Pradhan, Devish Pyakurel, Bijay Bhandari, Abha Shrestha
5 Survey on stat tests in Catalan clinical laboratories
Ariadna Arbiol-Roca, Dolors Dot-Bach
6 Critical results reporting in Portuguese hospital laboratories
Dora Vuljanić, Margarida Pereira, Sérgio Santos, Ana Nikler, Vanja Radišić Biljak, Isabel Cachapuz
7 Diagnostic challenges with acyclovir crystalluria – a case study
Alicia R. Andrews, Darryl Yu, Andrew W. Lyon
8 Case report on paediatric nephrotic syndrome
Shireen Prince, Kunta Naresh, R. Tulasi
9 Aerococcus urinae spondylodiscitis: an increasingly described localization
Amina Lyagoubi, Chahrazad Souffi, Victoria Baroiller, Eric Vallee
10 A tarnished toy story
Michelle (k/a Mikhaila) Muscat

 

]]>